The Need: The treatment landscape for multiple myeloma (MM) demands novel, targeted solutions to improve patient outcomes. Existing therapies often fall short in addressing the complex challenges posed by MM, necessitating a more precise and effective approach.

The Technology: Our technology introduces chimeric antigen receptor (CAR) polypeptides designed to enhance adoptive cell transfer therapy specifically for targeting and eliminating MM cells. These CAR polypeptides feature an anti-CS1 binding agent within their ectodomain, enabling selective binding to CS1-expressing MM cells. Additionally, they incorporate a transmembrane domain and an endodomain, facilitating immune effector cell activation.

Commercial Applications:

• Precision therapy for multiple myeloma.
• Advancement of adoptive cell transfer in oncology.
• Potential treatment for other CS1-expressing cancers.

Benefits/Advantages:

• Targeted approach: Selective binding to CS1-expressing MM cells enhances specificity and reduces off-target effects.
• Enhanced efficacy: Activation of immune effector cells amplifies anti-tumor immune response.
• Versatile platform: Potential applicability across various cancer types with CS1 expression.
• Improved patient outcomes: Offers a promising therapeutic option for MM patients resistant to standard treatments.
• Advancement in personalized medicine: Paves the way for tailored treatments based on individual tumor profiles.